DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
- Company Intends to Refinance the Remainder of Secured Debt in 2017 -
- Continues Commitment to De-Levering the Company -
NEWARK, Calif., April 04, 2017 -- Depomed Inc., (NASDAQ:DEPO) today announced that, in accordance with its stated plans and the terms of the secured debt facility with Deerfield and Pharmakon Advisors, LP, the company prepaid $100 million of principal amount of its $475 million secured indebtedness. In addition, Depomed paid a prepayment fee of $4 million.
Under the terms of the 7-year loan agreement, which matures in 2022, Depomed intends to refinance the remainder of the $375 million secured indebtedness in 2017.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to the company’s expectations regarding refinancing and the risks detailed in the Company’s Securities and Exchange Commission filings, including the Company’s most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. The inclusion of forward-looking statements should not be regarded as a representation that any of the Company’s plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payers we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000
